ECSP12011787A - Polipéptidos para unión al "receptor para productos finales de glicosilación avanzada" así como composiciones y métodos que implican a los mismos - Google Patents

Polipéptidos para unión al "receptor para productos finales de glicosilación avanzada" así como composiciones y métodos que implican a los mismos

Info

Publication number
ECSP12011787A
ECSP12011787A ECSP12011787A ECSP12011787A EC SP12011787 A ECSP12011787 A EC SP12011787A EC SP12011787 A ECSP12011787 A EC SP12011787A EC SP12011787 A ECSP12011787 A EC SP12011787A
Authority
EC
Ecuador
Prior art keywords
polypeptide
rpfga
polipeptides
glycosilation
involve
Prior art date
Application number
Other languages
English (en)
Inventor
Jochen Huber
Francis Blanche
Tarik Dabdoubi
Fabienne Soubrier
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09290778A external-priority patent/EP2308896A1/en
Priority claimed from EP09290845A external-priority patent/EP2319871A1/en
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of ECSP12011787A publication Critical patent/ECSP12011787A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

La presente invención se refiere a un polipéptido o complejo polipeptídico que comprende al menos dos secuencias de aminoácidos dispuestas de tal modo que se permita la unión específica del "receptor para productos finales de glicosilación avanzada" (RPFGA), uno o más ácido(s) nucleico(s) que codifica(n) para el polipéptido o complejo polipeptídico, una célula que produce un anticuerpo contra RPFGA, una composición farmacéutica que comprende al menos un polipéptido o ácido nucleico como se ha definido anteriormente, opcionalmente para tratar una enfermedad o trastorno relacionado con RPFGA y un método para diagnosticar una enfermedad o trastorno relacionado con RPFGA.
ECSP12011787 2009-10-09 2012-04-05 Polipéptidos para unión al "receptor para productos finales de glicosilación avanzada" así como composiciones y métodos que implican a los mismos ECSP12011787A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09290778A EP2308896A1 (en) 2009-10-09 2009-10-09 Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
EP09290845A EP2319871A1 (en) 2009-11-05 2009-11-05 Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same

Publications (1)

Publication Number Publication Date
ECSP12011787A true ECSP12011787A (es) 2012-10-30

Family

ID=43448431

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011787 ECSP12011787A (es) 2009-10-09 2012-04-05 Polipéptidos para unión al "receptor para productos finales de glicosilación avanzada" así como composiciones y métodos que implican a los mismos

Country Status (19)

Country Link
US (1) US20120282637A1 (es)
EP (1) EP2486058A1 (es)
JP (1) JP2013507115A (es)
KR (1) KR20120089863A (es)
CN (1) CN102686611A (es)
AU (1) AU2010305374A1 (es)
BR (1) BR112012007821A2 (es)
CA (1) CA2777237A1 (es)
CL (1) CL2012000886A1 (es)
CR (1) CR20120139A (es)
EC (1) ECSP12011787A (es)
IL (1) IL218968A0 (es)
MA (1) MA33661B1 (es)
MX (1) MX2012004090A (es)
PE (1) PE20121689A1 (es)
RU (1) RU2558301C2 (es)
TN (1) TN2012000138A1 (es)
WO (1) WO2011042548A1 (es)
ZA (1) ZA201202099B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
GB201200563D0 (en) * 2012-01-13 2012-02-29 Imp Innovations Ltd Binding molecule
WO2014167826A1 (ja) * 2013-04-08 2014-10-16 株式会社免疫生物研究所 アミロイド前駆体タンパク質のα－セクレターゼ切断後のＣ末端側断片の切断面を特異的に認識する抗体及びその利用
WO2014197460A1 (en) * 2013-06-04 2014-12-11 The Trustees Of The University Of Pennsylvania Methods for diagnosing and treating bicuspid aortic valve and/or aortopathies
WO2015031815A2 (en) 2013-08-30 2015-03-05 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
EP3633381A3 (en) 2013-12-05 2020-07-29 The Broad Institute, Inc. Compositions and methods for identifying and treating cachexia or pre-cachexia
US20170240632A1 (en) * 2014-10-16 2017-08-24 The Broad Institute Inc. Compositions and methods for identifying and treating cachexia or pre-cachexia
JP6679096B2 (ja) * 2014-10-21 2020-04-15 学校法人 久留米大学 Ｒａｇｅアプタマーおよびその用途
EP3223865A4 (en) * 2014-10-31 2018-10-03 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind b7-h4
KR20180023900A (ko) * 2015-05-12 2018-03-07 신티뮨, 인크. 인간화된 친화성 성숙 항-FcRn 항체
EP3297663A4 (en) 2015-05-18 2018-12-19 Agensys, Inc. Antibodies that bind to axl proteins
US10787516B2 (en) 2015-05-18 2020-09-29 Agensys, Inc. Antibodies that bind to AXL proteins
WO2016201319A1 (en) * 2015-06-10 2016-12-15 The Broad Institute Inc. Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia
EP3307781B8 (en) 2015-06-10 2020-12-02 The Broad Institute, Inc. Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia
JP6578595B2 (ja) * 2015-08-28 2019-09-25 国立研究開発法人科学技術振興機構 抗アセチル化ヒストンｈ４抗体
CN107922499B (zh) * 2015-09-08 2021-08-27 卫材R&D管理有限公司 抗EphA4抗体
IL257531B2 (en) 2015-09-17 2023-04-01 Immunogen Inc Medicinal compositions containing anti-folr1 immunoconjugates
US11111296B2 (en) 2015-12-14 2021-09-07 The Broad Institute, Inc. Compositions and methods for treating cardiac dysfunction
CN113512111B (zh) * 2017-03-10 2023-08-15 北京天广实生物技术股份有限公司 抗埃博拉病毒单克隆抗体、其制备方法及用途
US11401329B2 (en) 2017-08-02 2022-08-02 Phanes Therapeutics, Inc. Anti-CD47 antibodies and uses thereof
EP3773718A4 (en) 2018-04-06 2022-01-19 aTyr Pharma, Inc. COMPOSITIONS AND METHODS WITH ANTI-NRP2 ANTIBODIES
US11345744B2 (en) 2019-05-07 2022-05-31 William R Church Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same
WO2020261097A1 (en) * 2019-06-26 2020-12-30 Glaxosmithkline Intellectual Property Development Limited Il1rap binding proteins
WO2021067761A1 (en) * 2019-10-03 2021-04-08 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
WO2022019924A1 (en) * 2020-07-23 2022-01-27 Church William R Antibody specific to staphylococcus aureus, therapeutic method and detection method using same
CN113956363B (zh) * 2021-10-13 2023-03-31 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和cd24的重组融合蛋白及其制备和用途
CN116554311B (zh) * 2023-05-04 2023-11-21 中国人民解放军军事科学院军事医学研究院 抗CD2v-N的特异性抗体及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6194388B1 (en) 1994-07-15 2001-02-27 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US5864018A (en) * 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
ZA988461B (en) * 1997-09-18 1999-03-30 Idec Pharma Corp Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
DE60100814T2 (de) 2000-06-08 2004-07-01 Intercell Biomedizinische Forschungs- Und Entwicklungs Gmbh Immunstimulierende oligodeoxynukleotide
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
JP2004506019A (ja) 2000-08-17 2004-02-26 インターツェル・アクチェンゲゼルシャフト 少なくとも１つの抗原およびカテリシジン由来の抗菌ペプチドまたはその誘導体を含むワクチン
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
AU2002320762B2 (en) 2001-05-21 2006-09-21 Intercell Ag Immunostimulatory oligodeoxynucleic molecules
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US20080008719A1 (en) * 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
RU2008139098A (ru) * 2006-03-02 2010-04-10 Онкотерапи Сайенс, Инк. (Jp) Способы диагностики рака поджелудочной железы с применением белка reg4
CN101448857A (zh) * 2006-03-21 2009-06-03 惠氏公司 预防和治疗淀粉样蛋白生成疾病的方法
EP2001907A2 (en) * 2006-03-21 2008-12-17 Wyeth a Corporation of the State of Delaware Methods and compositions for antagonism of rage
EP2035456A1 (en) * 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
CN100586960C (zh) * 2006-06-23 2010-02-03 陈志南 HAb18GC2单抗和其轻、重链可变区基因及应用
WO2008137552A2 (en) * 2007-05-02 2008-11-13 Medimmune, Llc Anti-rage antibodies and methods of use thereof
BRPI0911758A8 (pt) * 2008-05-09 2017-10-10 Abbott Lab Anticorpos para receptor de produtos finais de glicação avançada (rage) e utilizações dos mesmos

Also Published As

Publication number Publication date
CL2012000886A1 (es) 2012-12-14
WO2011042548A1 (en) 2011-04-14
MX2012004090A (es) 2012-04-20
RU2012118598A (ru) 2013-11-20
ZA201202099B (en) 2012-11-28
BR112012007821A2 (pt) 2017-05-30
AU2010305374A1 (en) 2012-05-03
US20120282637A1 (en) 2012-11-08
CN102686611A (zh) 2012-09-19
JP2013507115A (ja) 2013-03-04
IL218968A0 (en) 2012-07-31
PE20121689A1 (es) 2012-12-14
EP2486058A1 (en) 2012-08-15
MA33661B1 (fr) 2012-10-01
CR20120139A (es) 2012-07-13
CA2777237A1 (en) 2011-04-14
RU2558301C2 (ru) 2015-07-27
KR20120089863A (ko) 2012-08-14
TN2012000138A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
ECSP12011787A (es) Polipéptidos para unión al "receptor para productos finales de glicosilación avanzada" así como composiciones y métodos que implican a los mismos
BR112014012789A2 (pt) agentes terapêuticos compreendendo sequências de aminoácidos de insulina
BR112012015740A2 (pt) anticorpos de anti-flt3 e metodos de uso dos mesmos
BR112014008694A2 (pt) moléculas de ácido nucleico policistrônico recombinante
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
NZ705370A (en) Fcγriib-specific fc region variant
CO6290770A2 (es) Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardado
MY183588A (en) New salvianolic acid compound l, preparation method and use thereof
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
MX355428B (es) Formas cristalinas del acido [ (4-hidroxi-1-metil-7-fenoxi-isoquin olin-3-carbonil) -amino] -acetico inhibidor de prolil hidroxilasa.
BR112015012933A2 (pt) proteínas de ligação ao antígeno bcma
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
MY178926A (en) Bispecific anti-vegf/anti-ang-2 antibodies
MY195289A (en) Anti IL-36R Antibodies
EA201501122A1 (ru) Новые агонисты соматостатиновых рецепторов подтипа 4 (sstr4)
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
BR112013032434A2 (pt) restauração dentária, método para sua produção e vidro cerâmico
EA200970247A1 (ru) Способ получения оптического активного n-защищенного 3-аминопирролидина или оптически активного n-защищенного 3-аминопиперидина и соответствующих кетонов путем оптического разделения рацемических смесей аминов с использованием бактериальной омега-трансаминазы
SG178886A1 (en) Humanized anti-cdcp1 antibodies
IN2012MN02923A (es)
MY161268A (en) PEPTIDE OR PEPTIDE COMPLEX BINDING TO α2 INTEGRIN AND METHODS AND USES INVOLVING THE SAME
EA201391489A1 (ru) Композиции со сниженной вязкостью
MX359854B (es) Anticuerpos anti-cxcr3.
CL2014003464A1 (es) Método para mejorar la integridad deteriorada de la unión neuromuscular que comprende la administración de una composición que comprende un vector viral adeno-asociado recombinante (raav) que comprende una molécula de ácido nucleico que codifica la alfa-glucosidasa ácida (gaa).